Cost-effectiveness of lenalidomide plus rituximab versus rituximab monotherapy in patients with previously treated follicular lymphoma: a societal view

Frederick W. Thielen,Marie José Kersten,Pim Kuizenga,Mels Hoogendoorn,Eduardus F. M. Posthuma,Wendy Stevens,Carin A. Uyl-de Groot,Hedwig M. Blommestein

Cost-effectiveness of lenalidomide plus rituximab versus rituximab monotherapy in patients with previously treated follicular lymphoma: a societal view

2021

Frederick W. Thielen
Marie José Kersten
Pim Kuizenga
Mels Hoogendoorn
Eduardus F. M. Posthuma
Wendy Stevens
Carin A. Uyl-de Groot
Hedwig M. Blommestein

Efficacy of lenalidomide plus rituximab (R-LEN) compared to rituximab monotherapy (R-mono) for patients with previously treated follicular lymphoma (FL) was investigated in AUGMENT (NCT01938001). O...

Keywords:

Cost–utility analysis
in patient
MEDLINE
Internal medicine
cost effectiveness
Oncology
Medicine
Follicular lymphoma
Lenalidomide
previously treated
Rituximab

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations